You are here

Angiochem to present data for oncology programs at American Association for Cancer Research Meeting

12-Apr-2010

–Targeting of LRP-1 Receptor: A New Therapeutic Approach for Cancers–

Montreal, Canada –Angiochem a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem’s EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

Poster Presentations:

  • Abstract #4417: Tuesday, April 20, 2010, 2:00 PM - 5:00 PM, “Uptake of the new paclitaxel-derivative (ANG1005) by the low-density lipoprotein receptor-related protein1 (LRP1) is related to the aggressive phenotype of glioblastoma cells,” Bertrand, et.al., Exhibit Hall A-C, Poster Section 22, Poster Board 6
  • Abstract #3578: Tuesday, April 20, 2010, 9:00 AM - 12:00 PM, “New Angiochem-modified doxorubicin with increased brain penetration and efficacy against brain tumors,” Demeule, et.al., Exhibit Hall A-C, Poster Section 24, Poster Board 26

About ANG1005 // ANG1005 has a novel mode of action, targeting the lipoprotein receptor-related protein (LRP-1) pathway. ANG1005 was  created with the Engineered Peptide Compounds (EPiC) platform which leverages the LRP-1 mediated pathway. Studies have shown that ANG1005 gains entry into the brain by targeting LRP-1, one of the most highly expressed receptors on the surface of the BBB.  ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including gliomas, Breast , Lung, Liver and Ovarian cancers.

About AngioChem // Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier (BBB) to treat brain diseases. The company’s proprietary Engineered Peptide Compounds (EPiC) technology creates drugs that cross the BBB and reach therapeutic concentration in the brain, by harnessing naturally-occurring receptors on the surface of the BBB. Angiochem’s lead product candidate, ANG1005 is in two separate clinical studies in patients with brain cancers and cancer metastases. Additionally, Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the potential treatment of a wide range of CNS diseases, including neurodegenerative and metabolic diseases, brain cancer, psychiatric disorders and many others. Founded in 2006, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit : http://www.angiochem.com.